New treatment to reverse opioid overdose
Official title: Novel Therapeutic Agents to Reverse Opioid Overdose
Funded at Clear Scientific, LLC · NIH-10492707 · Data updated 2026-11-12
This study is testing a new injection called CS-1103 that aims to quickly reverse the effects of fentanyl overdoses, offering a potentially better option than the usual treatment, naloxone, for people who might need help in an emergency.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Clear Scientific, LLC NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | September 30, 2020 |
| Project end | August 31, 2025 |
| Funding year | 2022 |
| Award (this year) | $1,245,607 |
| NIH project number | 5R44DA052957-03 |
| Project ID | NIH-10492707 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals at risk of opioid overdose, particularly those using fentanyl or its analogues.
✕Less likely to help
Patients who do not use opioids or are not at risk of overdose may not benefit from this research.
What this research studies
This research focuses on developing a new medication, CS-1103, that can quickly reverse the effects of fentanyl and its analogues, which are increasingly responsible for overdose deaths. Unlike naloxone, which is commonly used but less effective against fentanyl, CS-1103 works by binding to the drug in the bloodstream and helping to eliminate it from the body more rapidly. The goal is to create a formulation that can be administered via injection in emergency situations, providing a potentially life-saving option for individuals experiencing an opioid overdose. The research aims to optimize the dosage and formulation for effective use in real-world scenarios.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for reversing opioid overdoses, potentially saving countless lives.
How similar studies have gone: While naloxone has been widely used, this approach with CS-1103 represents a novel method that has not yet been tested in clinical settings.
Where this research is happening
-
Clear Scientific, LLC
Cambridge, United States Active
Researchers
- Principal investigator: Li, Xinhua — Clear Scientific, LLC
- Study coordinator: Li, Xinhua
Related research
Other NIH-funded projects on the same topics.
-
A rapid antidote for methamphetamine intoxication that can be given by IV
A phase 2a study tests CS-1103, a fast-acting treatment designed to reverse methamphetamine intoxication and help clear the drug from the body.
-
A new medicine to quickly reverse methamphetamine overdose
This project aims to develop a fast-acting medicine called CS-1103 to help people experiencing severe methamphetamine intoxication.
-
New antidote for overdoses involving fentanyl and xylazine
A new injectable medicine that quickly removes both fentanyl and xylazine to reverse sedation and breathing problems in people overdosing on these drugs.
-
A new treatment to quickly remove synthetic opioids from the body
This study is testing a new treatment called CS-1103 that helps quickly remove dangerous synthetic opioids like fentanyl from the body, aiming to provide a single dose that can restore normal breathing and keep people safe after an overdose.
-
Developing a new antidote for fentanyl and xylazine overdoses
This study is working on a new treatment to help people who have overdosed on a mix of fentanyl and xylazine, which regular naloxone can't fix, so that they can breathe better and feel more alert again.
-
Developing a fast-acting antidote for methamphetamine overdose
This study is testing a new treatment called CS-1103 that helps quickly remove methamphetamine from the body, making it safer for people who have overdosed on the drug, and it's aimed at helping emergency departments handle these situations better.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.